- Home
- DOMH vs TENX Comparison
DOMH vs TENX Comparison
Compare DOMH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- TENX
- Stock Information
- Founded
- DOMH 1967
- TENX 1967
- Country
- DOMH United States
- TENX United States
- Employees
- DOMH N/A
- TENX N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- TENX Health Care
- Exchange
- DOMH Nasdaq
- TENX Nasdaq
- Market Cap
- DOMH 12.1M
- TENX 11.4M
- IPO Year
- DOMH N/A
- TENX N/A
- Fundamental
- Price
- DOMH $1.61
- TENX $4.73
- Analyst Decision
- DOMH
- TENX Strong Buy
- Analyst Count
- DOMH 0
- TENX 4
- Target Price
- DOMH N/A
- TENX $20.67
- AVG Volume (30 Days)
- DOMH 11.9K
- TENX 68.7K
- Earning Date
- DOMH 11-08-2024
- TENX 11-13-2024
- Dividend Yield
- DOMH N/A
- TENX N/A
- EPS Growth
- DOMH N/A
- TENX N/A
- EPS
- DOMH N/A
- TENX N/A
- Revenue
- DOMH $12,589,000.00
- TENX N/A
- Revenue This Year
- DOMH N/A
- TENX N/A
- Revenue Next Year
- DOMH N/A
- TENX N/A
- P/E Ratio
- DOMH N/A
- TENX N/A
- Revenue Growth
- DOMH 1117.50
- TENX N/A
- 52 Week Low
- DOMH $1.50
- TENX $2.77
- 52 Week High
- DOMH $3.20
- TENX $33.44
- Technical
- Relative Strength Index (RSI)
- DOMH 44.56
- TENX 61.00
- Support Level
- DOMH $1.52
- TENX $4.50
- Resistance Level
- DOMH $1.77
- TENX $5.09
- Average True Range (ATR)
- DOMH 0.12
- TENX 0.24
- MACD
- DOMH -0.00
- TENX -0.03
- Stochastic Oscillator
- DOMH 43.33
- TENX 66.98
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.